Sony Pictures, Apollo Looking to Jointly Acquire Paramount, Propose $26 Billion Cash Deal 
Adidas Strategizes to Sustain Sneaker Sales Surge as Samba, Gazelle Drive Growth 
Comcast Drops Bally Sports Channels, Stops Broadcast of MLB Team Games 
KFC Japan Celebrates Children’s Day with Samurai Colonel Tradition 
Samsung Chief Lee Jae-yong Wraps Up Europe Visit, Includes Vatican and Zeiss 
Anthropic Launches Claude AI App on iPhone to Rival OpenAI’s ChatGPT 
Arby’s Unveils New Menu Additions Plus Beyoncé-Inspired Chardonnay-Infused Sauce 
2025 Sees SK hynix's HBM Chips Fully Booked Amidst AI Surge 
Major Victory for Bayer's Monsanto as Appeals Court Overturns $185 Million Award in Chemical Exposure Case 
Mercedes-Benz Financial Appoints Korean Unit’s CEO 
Boeing’s Starliner is about to launch − if successful, the test represents an important milestone for commercial spaceflight 
Coca-Cola Europacific Partners’ Finance Chief Resigns, Moves to Johnnie Walker’s Diageo Company 
Electric air taxis are on the way – quiet eVTOLs may be flying passengers as early as 2025 
Kellanova Beats Expectations with Strong Q1 Sales Amid Higher Prices 
Kakao Enhances AI Focus, Merges Kakao Brain Into Core Operations 
Booking Holdings Surpasses Wall Street Expectations with Strong Q1 Earnings Amidst Global Travel Surge 
Hyundai Motor Scales Up Hydrogen EV Truck Business in the US 
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 19, 2016 -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced participation in two upcoming scientific conferences.
- World Orphan Drug Congress – Washington, D.C. (April 20-22)
Eric Olson, Senior Director, Corporate Development will give a presentation entitled “A novel AAV-based gene therapy platform for the treatment of rare diseases” at 4:00pm EDT on Thursday, April 21 during which he will discuss AGTC’s proprietary gene therapy platform.
- Retinal Cell and Gene Therapy Innovation Summit – Seattle, Wash. (April 28-29)
Jeff Chulay, M.D., DTM&H, Vice President and Chief Medical Officer, will lead a session about AGTC’s clinical development programs on Thursday, April 28 entitled “Development of AAV Gene Therapy Vectors for Achromatopsia and X-Linked Retinitis Pigmentosa.”
About AGTC
AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function, and which currently lack effective medical treatments.
AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis, X-linked retinitis pigmentosa, achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and early research studies in additional indications. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
IR/PR CONTACTS: David Carey (IR) or Danielle Lewis (PR) Lazar Partners Ltd. T: (212) 867-1768 or (212) 843-0211 [email protected] or [email protected] CORPORATE CONTACTS: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204 [email protected] Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected]
